Form 8-K - Current report:
SEC Accession No. 0000950170-24-122822
Filing Date
2024-11-07
Accepted
2024-11-07 08:05:09
Documents
13
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K hlvx-20241107.htm   iXBRL 8-K 39665
2 EX-99.1 hlvx-ex99_1.htm EX-99.1 88321
3 GRAPHIC img15426271_0.jpg GRAPHIC 10838
  Complete submission text file 0000950170-24-122822.txt   263168

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT hlvx-20241107.xsd EX-101.SCH 24829
15 EXTRACTED XBRL INSTANCE DOCUMENT hlvx-20241107_htm.xml XML 4691
Mailing Address 321 HARRISON AVE, SUITE 500 BOSTON MA 02118
Business Address 321 HARRISON AVE, SUITE 500 BOSTON MA 02118 (617) 213-5054
HilleVax, Inc. (Filer) CIK: 0001888012 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41365 | Film No.: 241433290
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)